A Third Idenix Nuc Put On Hold By FDA For Safety Concerns
This article was originally published in The Pink Sheet Daily
Executive Summary
The Massachusetts biotech faces yet another FDA development hold, this time on one of its preclinical HCV programs, but is staying tight-lipped about what the issues are.